Microsoft word - ditropan xl flash email edit_revised_fnl.doc

DITROPAN XL Flash E-Mail Impactful Openers
1. Overactive bladder dysfunction is estimated to affect over 33 million patients in the United States.
In your practice, how many patients do you see weekly that suffer from symptoms of urgency, frequency and/ -or urge urinary incontinence?
2. Doctor, last time I was here, you explained to me that efficacy and tolerability are the most
important considerations for you when choosing an OAB medication. Today, I’d like to share with you how DITROPAN XL can meet the needs of your new-start patients by offering the concept of flexible dosing to optimize efficacy and tolerability.
3. Doctor, many of your peers have successfully treated a broad range of OAB patients utilizing the
10 mg starting dose of DITROPAN XL, and optimized the dose as needed up to 30 mg. What has been your experience thus far with DITROPAN XL for your new-start patients?
1. When selecting an overactive bladder medication for your new-start patients, is efficacy the most
important feature you look for? Which efficacy parameters do you find to be the most important?
2. When a patient complains of symptoms or urgency, frequency and / or urge urinary incontinence,
which OAB medication do you select and why?
3. When you leave the examination room and head to the sample closet, what is the most important
feature of the OAB medication you are about to select?

Effective Closes
1. Doctor, given the information I’ve shared with you today regarding the efficacy and tolerability of
DITROPAN XL, will you give DITROPAN XL 10 mg a fair trial with your new-start patients complaining of symptoms of urgency, frequency and urge urinary incontinence?
2. Now that you’ve agreed that Ditropan XL’s flexible dosing option helps optimize efficacy and
tolerability for a broad range of your overactive bladder patients, will you prescribe Ditropan XL 10 mg 1st line?
3. We’ve discussed the clear efficacy, tolerability, and managed care-preferred status of Ditropan XL
(for you overactive bladder patients). Is there anything preventing you from giving DITROPAN XL a fair trial with your new-start patients?
The Call – What Good Looks Like Physician (prior call statement): “I reserve DITROPAN XL as my silver bullet. When all else fails, I use DITROPAN XL.” Representative: “Doctor, last time I was in you told me that you reserve DITROPAN XL for your more challenging OAB patients. Can you tell me why you only use DITROPAN XL for those difficult to treat patients?” Physician: “Well, I’ve always considered DITROPAN XL to be a very efficacious drug, but because it is such a potent product, my patients don’t tolerate it as well. So I tend to reserve it for my wet patients, or those that that fail other therapies.” Representative: “That’s interesting – what tolerability issues have your patients reported to you?” Physician: “I have had some patient complaints of dry mouth. I’ve even heard from some of your competitors that DITROPAN XL may cause more cognitive impairment in elderly patients than other OAB products.” Representative: “Doctor, as I’m sure you know, dry mouth is a class effect of the anti-cholinergic agents. When looking at the incidence of dry mouth with DITROPAN XL 10 mg in clinical studies, you will see that 71% of patients reported no dry mouth and only 1.2 % of patients actually discontinued due to dry mouth. In the OPERA trial (which compared the efficacy and tolerability of DITROPAN XL 10mg to DETROL LA 4 mg), 93 percent did not discontinue therapy due to dry mouth. As for the extended-release tolterodine treatment group, 95% did not discontinue due to dry mouth. Do you find this information relevant?” Physician: “Yes, I find it interesting.” Representative: “And as for CNS side effects, did the competitor reps show you any data to support their claims that DITROPAN XL causes more CNS effects in the elderly than other OAB products?” Physician: “No, they basically showed me how their medications would not cause CNS-related side effects.” Representative: “That’s very interesting doctor. Again, as with any anti-cholinergic medication, there is the possibility of CNS-related side effects. Although studies were not designed to specifically look at cognitive impairment, studies showed that 90% of the patients taking DITROPAN XL 10 mg (shown here in the DITROPAN XL Visual Aid) reported no CNS-related side effects. Today, I will leave an article published in the American Journal of Obstetrics andGynecology, June 2005 in which Doctor Chu did a sub-analysis of the OPERA trial comparing DITROPAN XL and DETROL LA, and CNS adverse events were not reported in 91% of the patients taking DITROPAN XL and 92% taking Detrol LA. With this being said, wouldn’t you agree that the primary goal for your patients suffering with urgency, frequency and/or urge urinary incontinence is to have relief of these symptoms?”
Physician: “Yeah, I guess your right.” Representative: “When looking at efficacy, DITROPAN XL 10 mg will provide the symptom relief they require. In clinical studies, DITROPAN XL had a 50 % reduction from baseline in mean urge urinary incontinence episodes in just 2 weeks. At 12 weeks, patients experienced a 70% reduction in urge urinary incontinence episodes. When looking at frequency versus baseline, DITROPAN XL had 28 less voids per week at the 12 week mark. And when optimally dosed between 5-30 mg, 43% of patients experienced total dryness. Don’t you think your patients could benefit from efficacy like this?” Physician: “You make a compelling case Mike. I’ll give it a shot.” Representative: “Just as a reminder, Dr. Lutz, because DITROPAN XL is preferred on 75% of your third party payers including United and Cigna Healthcare, you may actually save your patients between $100 - $200 in co-pays a year. Thanks for your commitment to try DITROPAN XL first line… I’ll check back in with you the Friday after next to see what your patients’ experience with DITROPAN XL 10 mg is consistent with the information I have shared with you today.”